Skip to main content
AZTR
NYSE Life Sciences

Young Pharmaceuticals Discloses 5.22% Azitra Stake, Plans Board Engagement

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.63
Mkt Cap
$3.8M
52W Low
$0.518
52W High
$4.995
52W Position info
22% above low
Off High info
87% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

AZTR sits 22% above its 52-week low of $0.518 on light trading volume (0.1× avg).

Summary

Young Pharmaceuticals disclosed a 5.22% open-market stake in Azitra (~$344,000) and said it will push the board and management on stockholder-value initiatives, including possible business combinations and board changes.


Key Events · Ownership and Investor Activity · AZTR

  • 5.22% Stake Disclosed

    Young Pharmaceuticals, Inc. beneficially owns 316,300 Azitra shares, or 5.22% of the 6,060,435 shares outstanding per the November 12, 2026 10-Q.

  • Open-Market Accumulation

    The stake was built through open-market purchases totaling approximately $343,977.15, including 238,500 post-split shares bought in the past 60 days for approximately $198,992.70 at $0.698–$1.4390 per share.

  • Activist Intent Stated

    The filer says it intends to communicate with the board and management on enhancing stockholder value and may discuss business combinations, board composition and capitalization changes.

  • Strategic Buyer Profile

    Young Pharmaceuticals is itself a developer and marketer of dermatological and aesthetic skincare products, making the stake potentially strategic rather than purely financial.


Analysis · AZTR · Life Sciences

A dermatology and aesthetic skincare company has just disclosed a 5.22% stake in Azitra, bought entirely in the open market for roughly $344,000, and it explicitly says it will engage the board and management on ways to enhance stockholder value — including possible business combinations, board composition and capitalization changes. That turns a passive holder into a potential activist voice at a company that just reported a $2.95M quarterly net loss, $3.75M of cash and going-concern doubt. Because the buyer is a strategic operator in the same skincare space, the stake could precede a partnership or a deal rather than just a financial trade. The purchases were made at $0.70–$1.44 per share, well above today's $0.63, meaning the buyer is already underwater on the position.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AZTR was trading at $0.63 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.8M. The 52-week trading range was $0.52 to $5.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AZTR - Latest Insights

AZTR
Nov 12, 2026, 4:13 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.7224
Real-time Price: $0.5805 info
Change: -$0.1419 (-20%) info
Market Cap: $3.8M info